Abon Biopharma has a total of 348 patents globally, out of which 257 have been granted. Of these 348 patents, more than 39% patents are active. China is where Abon Biopharma has filed the maximum number of patents, followed by United States of America and Hong Kong (S.A.R.). Parallelly, China
Centaurus Biopharma has a total of 418 patents globally, out of which 238 have been granted. Of these 418 patents, more than 64% patents are active. China is where Centaurus Biopharma has filed the maximum number of patents, followed by United States of America and Europe. Parallelly, China seems to
89Bio has a total of 77 patents globally, out of which 42 have been granted. Of these 77 patents, more than 87% patents are active. United States of America is where 89Bio has filed the maximum number of patents, followed by Canada and Hong Kong (S.A.R.). Parallelly, United States of
Invirsa has a total of 45 patents globally, out of which 23 have been granted. Of these 45 patents, more than 93% patents are active. United States of America is where Invirsa has filed the maximum number of patents, followed by Japan and Europe. Parallelly, United States of America seems
Amphastar Pharmaceuticals has a total of 211 patents globally, out of which 125 have been granted. Of these 211 patents, more than 45% patents are active. China is where Amphastar Pharmaceuticals has filed the maximum number of patents, followed by United States of America and Europe. Parallelly, United States of
Aavantibio has a total of 12 patents globally. Of these 12 patents, more than 91% patents are active. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Aavantibio. Aavantibio was founded in 2017. AavantiBio is a biopharmaceutical company that
Meissa Vaccines has a total of 12 patents globally, out of which no patents have been granted. Of these 12 patents, more than 91% patents are active. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Meissa Vaccines. Meissa
Veramorph has a total of 3 patents globally. Of these 3 patents, more than 66% patents are active. The United States of America and Europe (EPO) are where Veramorph has filed all their patents. Parallelly, The United States of America seems to be the main focused R&D center and also
Umoja Biopharma has a total of 59 patents globally, out of which no patents have been granted. Of these 59 patents, more than 88% patents are active. Europe is where Umoja Biopharma has filed the maximum number of patents, followed by Canada and Singapore. Parallelly, United States of America seems
Fzata has a total of 13 patents globally, out of which no patents have been granted. Of these 13 patents, more than 76% patents are active. Canada is where Fzata has filed the maximum number of patents, followed by the United States of America and Europe. Parallelly, United States of
Interested in in-depth patent data and patent portfolio analysis of Tesla. Get your report now.